With gene therapy closing in on hemophilia, BioMarin expands in North Bay

Rare-disease drug developer BioMarin Pharmaceutical Inc. is expanding its Novato manufacturing facility as it pushes into a final clinical trial for its experimental gene therapy for hemophilia A. The facility, expected to come on line in the third quarter, is significant in the emerging field of gene therapy because only a few companies have taken on the commitment of actually making their drugs in-house. Most gene therapy companies have opted to use contract manufacturers, at least throug h clinical…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news